Xponance’s Apogee Therapeutics APGE Stock Holding History

Xponance’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$314K	Buy	3,733 +718	+24%	+$52.1K	﹤0.01%	1245
2025 Q4	$228K	Buy	+3,015	New	+$190K	﹤0.01%	1323

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Xponance's APGE Position: Q1 2026 in Review

Xponance increased its Apogee Therapeutics (APGE) stake by 24% in Q1 2026, buying an estimated $52.1K and bringing the position to 3,733 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

Xponance first reported a position in APGE in Q4 2025 and has held it in 2 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

Xponance held 3,733 shares of Apogee Therapeutics worth $314K as of Q1 2026.
Xponance bought 718 Apogee Therapeutics shares in Q1 2026, an estimated $52.1K.
Apogee Therapeutics made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1245 holding.
Xponance first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 2 quarters since.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.